| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | CAS2; CASL; HEF1; CAS-L; CASS2 |
| WB Predicted band size | 93 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human NEDD9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NEDD9抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*"NEDD9 promotes invasiveness and EMT in cancer cells through regulation of FAK and TGF-β signaling"*
**作者**：Li et al.
**摘要**：该研究利用NEDD9特异性抗体进行免疫沉淀和Western blot分析，发现NEDD9通过增强FAK激酶活性及促进TGF-β信号通路，驱动癌细胞的上皮-间质转化(EMT)和侵袭转移。
2. **文献名称**：*"Role of NEDD9 in neural crest cell migration and adhesion"*
**作者**：Smith et al.
**摘要**：通过免疫荧光和NEDD9抗体标记，研究揭示了NEDD9在神经嵴细胞迁移中的关键作用，表明其通过调控细胞骨架重组和黏着斑动态影响胚胎发育。
3. **文献名称**：*"NEDD9 as a prognostic biomarker in triple-negative breast cancer"*
**作者**：Wang & Zhang
**摘要**：研究使用NEDD9抗体进行组织芯片(IHC)染色，发现NEDD9高表达与三阴性乳腺癌患者的不良预后显著相关，提示其作为潜在治疗靶点的价值。
以上文献均通过NEDD9抗体验证其在肿瘤转移、发育生物学及临床诊断中的功能。
NEDD9 (Neural precursor cell expressed developmentally downregulated 9), also known as HEF1 or CAS-L, is a scaffolding protein belonging to the Cas (Crk-associated substrate) family. It plays a critical role in regulating diverse cellular processes, including cell adhesion, migration, proliferation, and apoptosis, by integrating signals from integrins, growth factor receptors, and other extracellular cues. Structurally, NEDD9 contains multiple protein interaction domains, such as SH3-binding motifs and a C-terminal focal adhesion-targeting region, enabling it to interact with key signaling molecules like FAK, Src kinase, and Crk. Its dysregulation has been implicated in cancer progression, particularly in metastasis, as it enhances invasiveness by promoting epithelial-mesenchymal transition (EMT) and matrix metalloproteinase secretion.
NEDD9 antibodies are essential tools for studying its expression patterns, post-translational modifications, and interactions in both physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to quantify protein levels in tissues or cell lines. Researchers also employ them to investigate NEDD9’s role in signaling pathways, tumor microenvironments, and therapeutic resistance. Notably, elevated NEDD9 expression correlates with poor prognosis in cancers like melanoma, breast cancer, and glioblastoma, making it a potential biomarker and therapeutic target. Validation of antibody specificity remains crucial, as cross-reactivity with other Cas family members (e.g., p130Cas/BCAR1) may occur. Ongoing studies continue to explore NEDD9’s involvement in non-cancer conditions, including neurological disorders and immune regulation.
×
